NCT04982549 2021-08-06
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
Shandong Cancer Hospital and Institute
Phase 2 Unknown
Shandong Cancer Hospital and Institute
The First Affiliated Hospital of Guangzhou Medical University
Protgen Ltd
Zhejiang Cancer Hospital